Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Lymphoid 1

Conditions

Mucositis 1Lymphoma 1Hodgkin Disease 1

Interventions

naloxegol 7alvimopan 6Radiotherapy 5angiotensin I (1-7) 4Cisplatin 4tegaserod 3Injections 3RRx-001 2Fibroblast Growth Factor 7 2tempol 1prucalopride 1oxycodone naloxone combination 1naldemedine 1methylnaltrexone 1linaclotide 1licogliflozin 1hydrated silica gel-based toothpaste 1golotimod 1brilacidin 1apraglutide 1amlexanox 1aluminum hydroxide, magnesium hydroxide, drug combination 1Xylitol 1Water 1Therapeutics 1Testosterone Propionate 1Robotic Surgical Procedures 1Radiotherapy, Intensity-Modulated 1Phenylephrine 1Oxycodone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × apraglutide × Other × Clear all
NCT03417765 2024-10-24

Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas

VectivBio AG

Phase 1/2 Withdrawn
LymphoidOther

Hodgkin Disease, Lymphoma, Mucositis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡